Stability of new, iron-replete total nutrient admixtures

Information

  • Research Project
  • 6931797
  • ApplicationId
    6931797
  • Core Project Number
    R43DK071400
  • Full Project Number
    1R43DK071400-01
  • Serial Number
    71400
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2005 - 19 years ago
  • Project End Date
    6/30/2007 - 17 years ago
  • Program Officer Name
    FINKELSTEIN, DAVID B.
  • Budget Start Date
    7/1/2005 - 19 years ago
  • Budget End Date
    6/30/2007 - 17 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/17/2005 - 19 years ago

Stability of new, iron-replete total nutrient admixtures

[unreadable] DESCRIPTION (provided by applicant): There has been little progress in the treatment of iron deficiency anemia using a parenteral nutrient (PN) admixture with lipids as a suitable drug delivery vehicle. Currently approved parenteral iron colloids (e.g., iron dextrans) destabilize total nutrient admixtures with lipids and also present safety risks to the patient. This project will assess the safety and efficacy of a new approach for treatment of iron-deficiency anemia in which iron is delivered in clinically relevant total nutrient admixtures prepared using a monomeric iron complex that has unique binding characteristics that limit the amount of free iron. In Phase I the physicochemical stability of the new iron-replete PN admixtures will be evaluated using a multifactorial research design that has been validated for this application. The results will be compared with those obtained in identical assessments of PN admixtures containing iron dextrans. If iron-replete PN admixture stability is found, the Phase II clinical study will evaluate (1) the efficacy of iron-replete TPN admixtures in treating or preventing the development of iron deficiency, compared with conventional TPN admixtures; and (2) the safety of iron-replete TPN admixtures, compared with conventional TPN admixtures, by monitoring adverse reactions manifesting clinically or on laboratory testing. Furthermore, this Phase II study will provide information regarding generation of free iron and oxidant stress following intravenous administration of the iron complex in this drug delivery vehicle. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    105364
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:105364\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOLINK LIFE SCIENCES, INC.
  • Organization Department
  • Organization DUNS
    031254357
  • Organization City
    CARY
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    27513
  • Organization District
    UNITED STATES